Drug Profile

Glucagon liquid - Latitude Pharmaceuticals

Alternative Names: Glucagon nanoemulsion - Latitude Pharmaceuticals; Nano-G; Stable liquid glucagon formulation - Latitude Pharmaceuticals

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Latitude Pharmaceuticals
Class Antihypoglycaemics; Pancreatic hormones
Mechanism of Action Glucagon receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

No development reported Hypoglycaemia

Most Recent Events

03 Apr 2012 Latitude Pharmaceuticals stable glucagon product (Nano-G) is available for licensing as of 03 Apr 2012. http://www.latitudepharma.com/
03 Apr 2012 Preclinical trials in Hypoglycaemia in USA (SC)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com